구조모아 (StructureMoa)항암 chemical structure spider web
방문타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | SHR-A1811 |
Overview Company | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Overview Modality | ADC |
Overview Target | HER2 |
Overview Indication | Gastric Cancer; HER2 + Gastric Cancer |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Positioning Key differentiator | novel enzyme-cleavable linker and delivers the topoisomerase I inhibitor payload, rezetecan, with a drug-to-antibody ratio of |
Technology Payload | rezetecan |
Technology Linker | cleavable linker and delivers the topoisomerase I inhibi |
MoA Mechanism | targeting the human epidermal growth factor receptor |
MoA Biomarker | HER2-positive |
PK/PD Species | Cynomolgus monkey, Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse, NHP, In vitro |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Cynomolgus monkey, Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse, NHP, In vitro |
Toxicology Major finding | interstitial lung disease was observed in 10 patients (2 |
Toxicology CRS | Reported |
Clinical Safety signal | interstitial lung disease was observed in 10 patients (2 |
Clinical Program phase | PHASE_3 |
타깃 · 모달리티 · 임상 근거 · 비임상 맥락으로 최대 5개 프로그램을 나란히 비교합니다. · 다음 갱신 D-6 · 마지막 9월 2일
현재 선택: 1개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | SHR-A1811 |
Overview Company | Suzhou Suncadia Biopharmaceuticals Co., Ltd. |
Overview Modality | ADC |
Overview Target | HER2 |
Overview Indication | Gastric Cancer; HER2 + Gastric Cancer |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
Overview Content status | Curated Core |
Overview Data Confidence | Data Confidence · High |
Overview Development Signal | Development Signal · Emerging |
Overview Approval status | Investigational |
Positioning Key differentiator | novel enzyme-cleavable linker and delivers the topoisomerase I inhibitor payload, rezetecan, with a drug-to-antibody ratio of |
Technology Payload | rezetecan |
Technology Linker | cleavable linker and delivers the topoisomerase I inhibi |
MoA Mechanism | targeting the human epidermal growth factor receptor |
MoA Biomarker | HER2-positive |
PK/PD Species | Cynomolgus monkey, Mouse, Human |
PK/PD Animal (cat.) | Human, Mouse, NHP, In vitro |
PK/PD Experiment | Pharmacokinetic |
Toxicology Species | Cynomolgus monkey, Mouse, Human |
Toxicology Animal (cat.) | Human, Mouse, NHP, In vitro |
Toxicology Major finding | interstitial lung disease was observed in 10 patients (2 |
Toxicology CRS | Reported |
Clinical Safety signal | interstitial lung disease was observed in 10 patients (2 |
Clinical Program phase | PHASE_3 |
추천 비교
추천 비교